Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.02.2023 | Case report

Vemurafenib

Acquired drug resistance in multisystem Langerhans-cell histiocytosis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Lyudovskikh E, et al. THE CASE OF ACQUIRED VEMURAFENIB RESISTANCE IN BRAF V600E POSITIVE MULTISYSTEM PEDIATRIC LCH. Pediatric Blood and Cancer 70 (Suppl. 1): S31, Feb 2023. Available from: URL: http://doi.org/10.1002/pbc.30097 [abstract] Lyudovskikh E, et al. THE CASE OF ACQUIRED VEMURAFENIB RESISTANCE IN BRAF V600E POSITIVE MULTISYSTEM PEDIATRIC LCH. Pediatric Blood and Cancer 70 (Suppl. 1): S31, Feb 2023. Available from: URL: http://​doi.​org/​10.​1002/​pbc.​30097 [abstract]
Metadaten
Titel
Vemurafenib
Acquired drug resistance in multisystem Langerhans-cell histiocytosis: case report
Publikationsdatum
01.02.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-33509-7

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Antineoplastics

Case report

Antineoplastics

Case report

Multiple drugs

Case report

Daratumumab